Agilis Biotherapeutics, Intrexon Announce Collaboration
December 31, 2013 at 08:38 AM EST
Agilis Biotherapeutics and Intrexon Corporation (NYSE: XON ), announced today an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich's ataxia (FRDA), a rare genetic neurodegenerative disease. See full press release (c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
